We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Despite Uncertainties, Biogen Preparing for Aducanumab Rollout Ahead of FDA Decision
Despite Uncertainties, Biogen Preparing for Aducanumab Rollout Ahead of FDA Decision
Biogen has been gearing up for a U.S. rollout of its controversial, closely-watched Alzheimer’s drug candidate aducanumab despite lingering questions about its chances of FDA approval that will finally be put to rest by the agency’s June 7 target date.